Testosterone Update

FACULTY
Mohit Khera, MD, MBA, MPH
Assistant Professor of Urology
Director, Laboratory for Andrology Research
Medical Director
Houston Hospital for Specialized Surgery
Baylor College of Medicine
Houston, Texas

INTENDED AUDIENCE
Urologists, endocrinologists, primary care physicians, cardiologists, chronic pain specialists, and other healthcare providers interested in the management and treatment of chronic pain and hypogonadism.

NEEDS ASSESSMENT
While opioids are appropriately used to manage chronic pain conditions, many prescribing physicians do not recognize their effects on the hypothalamic-pituitary-gonadal axis. Opioid-induced hypogonadism remains largely underrecognized. This is concerning because hypogonadism is associated with metabolic conditions, particularly metabolic syndrome, type 2 diabetes, obesity, and osteopenia/osteoporosis. Screening, recognition, and treatment by any provider seeing men who are at risk for hypogonadism should be encouraged. To optimize adherence, when treating patients with hypogonadism, clinicians should carefully select a testosterone formulation to match patient preference and needs.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be better able to:

Identify patients at risk for opioid-induced hypogonadism and refer or treat appropriately with testosterone therapy to improve patient outcomes
Examine with the patient the profile of each testosterone formulation when assessing which will best match his needs, thus ensuring adherence
Integrate hypogonadism treatment goals within the framework of managing men's health to improve quality of life and optimize overall health outcomes

ACCREDITATION AND CERTIFICATION
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Dannemiller and CogniMed Inc. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.

Dannemiller designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

There is no charge for this activity. Statements of Credit will be provided by e-mail following activity participation and upon completion and electronic submission of the posttest and evaluation to Dannemiller. A link to the evaluation form is provided upon completion of the activity. If you have any questions about your certificate, please e-mail cme@dannemiller.com.

CONTENT REVIEW STATEMENT
To resolve identified/potential conflicts of interest, the education content was fully reviewed by a physician member of the Dannemiller Clinical Content Review Committee who have no financial relationships with commercial interests. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.

DISCLOSURE STATEMENT
It is the policy of Dannemiller to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty participating in sponsored programs are expected to identify and reference off-label product use and disclose any significant relationships with those supporting the activity or any others whose products or services are discussed. The faculty for this activity has disclosed that there will be discussion about the use of products for non–FDA-approved indications.

In accordance with the Accreditation Council for Continuing Medical Education standards, parallel documents from other accrediting bodies, and Dannemiller policy, the following disclosures have been made:

Dannemiller Staff
Mark T. Nadeau, MD, MBA, FAAFP, Clinical Content Reviewer, has nothing to disclose.
Gordon Ringler, Project Manager, has nothing to disclose.

CogniMed Inc. Staff
Roseann MacLachlan, Senior Program Manager, has nothing to disclose.
Estelle Perera, Senior Director, Scientific Affairs and Program Design, and Medical Writer, has nothing to disclose.
Elizabeth Varga Stanton, Editor, has nothing to disclose.

Faculty
Mohit Khera, MD, MBA, MPH, receives research support from Allergan, Inc., and Auxilium Pharmaceuticals, Inc. He is a consultant for Coloplast and Slate Pharmaceuticals, Inc., and serves on the speakers bureaus of Auxilium Pharmaceuticals, Inc., and Eli Lilly and Company.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of Dannemiller and/or its agents. As in all educational activities, we encourage the practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. Dannemiller disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

This activity is supported by independent educational grants provided by Endo Pharmaceuticals, Inc., and Lilly USA, LLC.

This activity is an enduring material and consists of an audio recording. Successful completion is achieved by listening to the audio, reflecting on the content's implications in your practice, and completing the assessment component.

The estimated time to complete this activity is 0.25 hour.

This activity was originally released May 31, 2013, and is eligible for credit through May 31, 2014.

This activity was reviewed by an impartial content reviewer and by faculty. Faculty have final editorial control over the piece.